• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Welcome to EPAD

EPAD - the European Prevention of Alzheimer's Dementia Consortium - was an interdisciplinary research programme spanning public and private sector organisations across Europe, with 39 partners, ending October 2020.


Access the EPAD data
0
Partnering Organizations
0
Study Sites
0
Research Participants
  • One of our biggest learnings, after several efforts that didn’t yield the result that we hope for, was that we probably wanted to intervene much earlier. We see there is an opportunity to affect the disease early before significant damage is done and give these disease modifying drugs a chance to show what they can do. Number one is identifying accurately that population in terms of who would benefit most from pharmacological intervention. And the second main challenge is then how does one make decisions on outcomes, as to whether drugs are effective in a population that may well be entirely asymptomatic.

    Luc Truyen
    Vice-President Neuroscience External Affairs at Janssen R&D
  • Preventing the development of dementia in biomarker-positive people would be a fantastic step forward in our fight against Alzheimer’s disease. The EPAD and its novel trial concept will hopefully help speed up the drug discovery progress and bring us closer to this ambitious aim.

    Jean Georges
    Executive Director of Alzheimer Europe
  • EPAD is part of a global initiative that will make a fundamental difference to the understanding and management of Alzheimer’s disease in people with very early or no symptoms at all. This could be a game-changer. It is only possible because of the absolute commitment of academics, industry, policy makers and the public to work hand in hand to defeat this global threat.

    Prof Craig Ritchie
    EPAD Co-coordinator and Professor of the Psychiatry of Ageing at the University of Edinburgh
  • This project has numerous advantages over current approaches. These include the excellent pre-trial characterisation of research participants to inform selection and reduce screen failure, the establishment of the highest possible quality study sites across Europe, the rapid decision making on the likely success of a drug (or combination of drugs) in subsequent confirmatory trials as well as access to a shared placebo group.

    Serge Van der Geyten
    EPAD Coordinator and Director for Neuroscience External Affairs at Janssen Pharmaceutica NV

EPAD’s Objectives

Despite significant global investment, there have been no new drugs for Alzheimer’s disease for 20 years. There is an urgent need for new treatments.

Learn more

EPAD Partners

EPAD was a unique collaborative research effort. Our 39 partners across Europe were committed to transforming our understanding of Alzheimer’s disease.

Learn more


Share this page
FacebookTwitterLinkedInGoogle+
Latest News
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
  • Local actions to keep the EPAD Longitudinal Cohort data collection going
    2021-02-17
  • Neuronet releases its Knowledge Base dashboard
    2021-02-01
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the @RosetreesT workshop on neurodegenerative diseases. @craig_ritchie68 presented @IMI_EPAD & @AD_PREVENT (from 1:06:00). @brainhealthscot @AlzData youtu.be/PsAZ1T5MmBo twitter.com/brainhealthsco…

reply retweet favorite
8:01 am · 2021-03-04
Twitter
EPAD
EPAD
@IMI_EPAD

The latest @AlzheimerEurope #newsletter includes an article on the first local @IMI_EPAD community meeting held last month among the Scottish research sites and collaborators who have been involved in the EPAD Longitudinal Cohort Study. Read more here: bit.ly/Feb2021AEnews twitter.com/AlzheimerEurop…

reply retweet favorite
3:26 pm · 2021-03-03
Twitter
EPAD
EPAD
@IMI_EPAD

@AD_PREVENT @alzassociation @alzheimerssoc Congratulations to all the team 👏

reply retweet favorite
7:03 am · 2021-03-01
Twitter
EPAD
EPAD
@IMI_EPAD

.@AlzheimerEurope has published a new edition of its “Dementia in Europe” magazine. It includes a closing article on @IMI_EPAD. Our co-leads @craig_ritchie68 and Serge Van der Geyten, reflect on the achievements of the project. Download the PDF here: bit.ly/DementiaInEuro… twitter.com/AlzheimerEurop…

reply retweet favorite
12:40 pm · 2021-02-24
Twitter
EPAD
EPAD
@IMI_EPAD

Last week, we held the first local @IMI_EPAD community meeting among the Scottish research sites, collaborators, academics & scientists who have been involved in our Longitudinal Cohort Study and now continue to contribute to the study locally More info⤵️ ep-ad.org/2021/02/17/loc… pic.twitter.com/MTKmanCURk

reply retweet favorite
6:51 am · 2021-02-24
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.